EMA to go extra mile to facilitate joint safety study for valproate

In the course of its mandate to help companies carry out joint post-authorization safety studies under the EU pharmacovigilance legislation, the European Medicines Agency is planning to organize a teleconference/webinar for a new study concerning the anti-epileptic drug valproate so that interested companies may be introduced to each other and have the opportunity to interact and raise questions.